196 related articles for article (PubMed ID: 33463462)
1. Dual Aromatase-Sulphatase Inhibitors (DASIs) for the Treatment of Hormone Dependent Breast Cancer.
Banjare L; Jain AK; Thareja S
Mini Rev Med Chem; 2021; 21(20):3144-3165. PubMed ID: 33463462
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
Santen RJ; Leszczynski D; Tilson-Mallet N; Feil PD; Wright C; Manni A; Santner SJ
Ann N Y Acad Sci; 1986; 464():126-37. PubMed ID: 3524346
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
Santen RJ
Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
[TBL] [Abstract][Full Text] [Related]
4. 4- and 6-(p-Sulphamoylphenyl)androstenediones: Studies of aromatase inhibitor-based oestrone sulphatase inhibition.
Watari Y; Yamaguchi S; Takahashi M; Nagaoka M; Numazawa M
Steroids; 2010 Dec; 75(12):891-6. PubMed ID: 20546769
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitors in the treatment of breast cancer.
Brueggemeier RW; Hackett JC; Diaz-Cruz ES
Endocr Rev; 2005 May; 26(3):331-45. PubMed ID: 15814851
[TBL] [Abstract][Full Text] [Related]
6. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
Shields-Botella J; Chetrite G; Meschi S; Pasqualini JR
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):1-13. PubMed ID: 15748827
[TBL] [Abstract][Full Text] [Related]
7. Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer.
Ahmad I; Shagufta
Eur J Med Chem; 2015 Sep; 102():375-86. PubMed ID: 26301554
[TBL] [Abstract][Full Text] [Related]
8. A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity.
Wood PM; Woo LW; Humphreys A; Chander SK; Purohit A; Reed MJ; Potter BV
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):123-30. PubMed ID: 15862957
[TBL] [Abstract][Full Text] [Related]
9. New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death.
Cepa M; Correia-da-Silva G; da Silva EJ; Roleira FM; Borges M; Teixeira NA
BMC Cell Biol; 2008 Jul; 9():41. PubMed ID: 18652661
[TBL] [Abstract][Full Text] [Related]
10. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
Nakata T; Takashima S; Shiotsu Y; Murakata C; Ishida H; Akinaga S; Li PK; Sasano H; Suzuki T; Saeki T
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):455-60. PubMed ID: 14623544
[TBL] [Abstract][Full Text] [Related]
11. Aromatase inhibitors: rationale for use following antiestrogen therapy.
Yue W; Santen RJ
Semin Oncol; 1996 Aug; 23(4 Suppl 9):21-7. PubMed ID: 8824461
[TBL] [Abstract][Full Text] [Related]
12. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer.
Lønning PE; Dowsett M; Powles TJ
J Steroid Biochem; 1990 Mar; 35(3-4):355-66. PubMed ID: 2139151
[TBL] [Abstract][Full Text] [Related]
13. Reconsidering Aromatase for Breast Cancer Treatment: New Roles for an Old Target.
Caciolla J; Bisi A; Belluti F; Rampa A; Gobbi S
Molecules; 2020 Nov; 25(22):. PubMed ID: 33207783
[TBL] [Abstract][Full Text] [Related]
14. Estradiol as an anti-aromatase agent in human breast cancer cells.
Pasqualini JR; Chetrite GS
J Steroid Biochem Mol Biol; 2006 Jan; 98(1):12-7. PubMed ID: 16413774
[TBL] [Abstract][Full Text] [Related]
15. The potential of aromatase inhibitors in breast cancer prevention.
Santen RJ; Yue W; Naftolin F; Mor G; Berstein L
Endocr Relat Cancer; 1999 Jun; 6(2):235-43. PubMed ID: 10731115
[TBL] [Abstract][Full Text] [Related]
16. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway.
Santner SJ; Feil PD; Santen RJ
J Clin Endocrinol Metab; 1984 Jul; 59(1):29-33. PubMed ID: 6725522
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators.
Geisler J
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):245-53. PubMed ID: 14623518
[TBL] [Abstract][Full Text] [Related]
18. Estrogen signaling: An emanating therapeutic target for breast cancer treatment.
Saha T; Makar S; Swetha R; Gutti G; Singh SK
Eur J Med Chem; 2019 Sep; 177():116-143. PubMed ID: 31129450
[TBL] [Abstract][Full Text] [Related]
19. Control and expression of oestrone sulphatase activities in human breast cancer.
Pasqualini JR; Chetrite G; Nestour EL
J Endocrinol; 1996 Sep; 150 Suppl():S99-105. PubMed ID: 8943793
[TBL] [Abstract][Full Text] [Related]
20. Aromatase Inhibitors for the Treatment of Breast Cancer: A Journey from the Scratch.
Ratre P; Mishra K; Dubey A; Vyas A; Jain A; Thareja S
Anticancer Agents Med Chem; 2020; 20(17):1994-2004. PubMed ID: 32593281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
